Unveiling the role of single versus repeated low-dose ketamine in attenuating doxorubicin-induced chemobrain and depression in rats: differential modulation of neuroinflammation, phosphorylated GLT-1, SERT, DAT, and BDNF/TrkB signaling.
Neuropharmacology June 1, 2026 Nehal G. Fahmy, Nada M. Kamel, Mahmoud M. Khattab et al.
In rats, a single low dose of ketamine more effectively than repeated low doses counteracts cognitive impairment and depressive-like behavior caused by the chemotherapy drug doxorubicin. The single dose better reduced brain inflammation and normalized levels of glutamate transporter GLT-1, serotonin transporter SERT, dopamine transporter DAT, and brain-derived neurotrophic factor (BDNF)/TrkB signaling. Repeated dosing showed weaker or no benefits on these molecular markers.